The publication illustrates the clinical benefit of the combination of PreTRMÂ® tests with evidence-based interventions to improve neonatal health and reduce total health costs
Positive impact on preterm births, neonatal intensive care admissions, overall length of hospital stay and a net reduction of $ 54 million in total costs in the analyzed population
SALT LAKE CITY, September 14, 2021 (GLOBE NEWSWIRE) – Serum prognosis Inc., The Pregnancy Company â¢, focused on improving maternal and newborn health by providing innovative information on pregnancy biomarkers to physicians and patients, today announced the publication of a rigorous clinical and economic review using actual data from claims from a large population of Anthem-affiliated health plans. to assess the potential value of PreTRMÂ® testing and treatment strategy.
The study conservatively modeled the PreTRMÂ® strategy, consisting of proactive, evidence-based testing and interventions, within Anthem claims data from individual and employer-sponsored plans, and has shown both improved neonatal outcomes and reduced costs immediate and long-term treatment associated with preterm birth, compared to routine care. These results were published in the peer-reviewed journal ClinicoEconomics and Outcome Research in an article titled “Cost-effectiveness of a proteomic test for the prediction of preterm birth.”
“The publication of this data adds to the growing body of evidence supporting the effectiveness of Sera’s testing and treatment strategy in identifying women at risk for bPST and enabling evidence-based interventions to reduce the risk.” , thereby improving pregnancy outcomes while reducing the economic burden on payers and health care systems, âsaid Gregory C. Critchfield, MD, MS, president and CEO of Sera Prognostics. âWe look forward to discussing the implications of this data as we engage with employers and payers in our efforts to improve pregnancy outcomes and reduce healthcare costs through expanded access to PreTRM.Â® test.”
Study analysis was conducted by Sera in partnership with HealthCore, using claims data from more than 40,000 pregnant women and infants who were members of individual and employer-sponsored Anthem health plans. The analysis assessed the PreTRMÂ® test and treatment strategy by modeling the application of PreTRMÂ® test during weeks 19 or 20 of pregnancy, and evaluated the benefit of proactive interventions consisting of more intensive case management and monitoring, as well as pharmacological interventions for women identified as at highest risk by the test, whereas usual care was assumed for all women without higher PreTRMÂ® risk.
The main conclusions of the analysis include:
20% reduction in preterm births less than 37 weeks gestation
33% reduction in births under 32 weeks gestation
10% reduction in neonatal intensive care admissions
7% reduction in overall length of hospital stay
Net savings of $ 863 ($ 1,608 in gross savings) per pregnant woman, a reduction of $ 54 million in total costs compared to the study population
“The pre-MRTÂ® The testing and treatment strategy is associated with both better outcomes and lower total costs, which is rare among modern medical interventions, said Michael Grabner, senior scientist for HealthCore. “The results were consistent across a wide variety of possible scenarios in terms of test participation, treatment adherence, treatment effectiveness, and accumulated costs.”
Based on the study’s estimated net cost savings for the health care system of $ 863 saved per pregnant woman, the authors estimate that more than $ 850 million could be saved each year in individual-sponsored health plans. and employers in the United States, assuming full use of the test-and-treatment strategy. This is based on an assumption of around 4 million births per year, of which around 50% occur to women with such commercial health insurance, and further assuming that at least half have no risk factors. obvious premature labor.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide physicians with essential and early information about pregnancy, enabling them to improve the health of their patients, which translates into reduced health care delivery costs. Sera has a strong portfolio of innovative diagnostic tests focused on early prediction of the risk of preterm birth and other pregnancy complications. Precision medicine from Sera PreTRMÂ® The test reports the individualized risk of spontaneous preterm delivery during pregnancy to a doctor, allowing for earlier proactive interventions in women at higher risk. Sera Prognostics is located in Salt Lake City, Utah.
About premature birth
Premature birth is defined as any birth before 37 weeks gestation and is the leading cause of illness and death in newborns. The March of Dimes 2020 report shows that of about 3.8 million babies born each year in the United States, more than one in ten are born prematurely. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory disease, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the life of the children concerned. The annual health care costs for managing the short- and long-term complications of prematurity in the United States have been estimated at around $ 25 billion for 2016.
About PreTRMÂ® Test
The pre-MRTÂ® is the only commercially available widely clinically validated blood biomarker test that provides early, accurate and individualized prediction of the risk of spontaneous preterm delivery in asymptomatic single pregnancies. The pre-MRTÂ® test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The pre-MRTÂ® The test allows doctors to identify, in the 19th or 20th week of pregnancy, which women are at increased risk of preterm delivery, allowing for more informed and personalized clinical decisions based on each woman’s individual risk. . The pre-MRTÂ® the test is ordered by a healthcare professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc in the United States and / or other countries.
Safe Harbor Declaration
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to engagement with employers and payers to potentially expand access to PreTRM.Â® test; estimates of over $ 850 million to be saved each year assuming full adoption of the risk detection and treatment strategy; and the company’s strategic guidelines under the heading âAbout Sera Prognostics, Inc.â These âforward-looking statementsâ are based on management’s current expectations regarding future events and are subject to a number of risks and considerations. ‘uncertainties that could cause actual results to differ materially and adversely from those stated or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation and the potential need to raise more capital; income from the PreTRM test representing almost all of the Company’s income to date; the need for broad scientific and commercial acceptance of the PreTRM test; a concentrated number of hardware customers; our ability to introduce new products; potential competition; our exclusive biobank; critical suppliers; the ongoing COVID-19 pandemic and its impact on our operations, as well as the activities or operations of third parties with whom we do business; estimates of the total addressable market opportunity and market growth forecasts; potential coverage and reimbursement by a third party payment; the new reimbursement methodologies applicable to the PreTRM test, including the new CPT codes and the payment rates for these codes; changes in FDA regulations on lab-developed tests; intellectual property rights protecting our tests and our market position; and other factors discussed under the heading âRisk Factorsâ contained in our final prospectus on Form S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as well as any updates to these factors from time to time. in our quarterly reports on Form 10-Q, annual reports on Form 10-K or routine reports on Form 8-K. All information contained in this press release is as of the date of publication, and the Company does not undertake to update this information, except as required by law.
Peter DeNardo, CapComm Partners
+1 (415) 389-6400
Erich Sandoval, Lazar FINN
+1 (917) 497-2867